Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR8 | P51685 | 4/20 | 0.65 |
| ▸ | DRD4 | P21917 | 7/20 | 0.64 |
| ▸ | DRD2 | P14416 | 4/20 | 0.64 |
| ▸ | MCHR1 | Q99705 | 6/20 | 0.62 |
| ▸ | HTR2A | P28223 | 1/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6505380 | 1.00 | CCR8 (0.65) | CCR8DRD4DRD2MCHR1HTR2A | |
| SCHEMBL6496964 | 0.92 | CCR8 (0.66) | CCR8DRD4DRD2MCHR1HTR2A | |
| SCHEMBL6496971 | 0.92 | CCR8 (0.66) | CCR8DRD4DRD2MCHR1HTR2A | |
| SCHEMBL6506734 | 0.92 | CCR8 (0.66) | CCR8DRD4DRD2MCHR1HTR2A | |
| SCHEMBL6497857 | 0.90 | CCR8 (0.78) | CCR8DRD4DRD2KCNH2 | |
| SCHEMBL6500843 | 0.89 | CCR8 (0.66) | CCR8DRD4DRD2MCHR1KCNH2 | |
| SCHEMBL6500837 | 0.89 | CCR8 (0.66) | CCR8DRD4DRD2MCHR1KCNH2 | |
| SCHEMBL6505990 | 0.86 | CCR8 (0.62) | CCR8DRD4DRD2MCHR1KCNH2 | |
| SCHEMBL6505986 | 0.86 | CCR8 (0.62) | CCR8DRD4DRD2MCHR1KCNH2 | |
| SCHEMBL6505982 | 0.86 | CCR8 (0.62) | CCR8DRD4DRD2MCHR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143372-A1 | Compounds, pharmaceutical compositions and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143372-A1 | Compounds, pharmaceutical compositions and methods of use therefor | CCR8, CCL11, CCR5 | CCR8 1/4885DRD4 3663/4885DRD2 3014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.